Pulse Biosciences
3957 Point Eden Way
Hayward
CA
94545
United States
Tel: 510-906-4600
Website: https://www.pulsebiosciences.com/
About Pulse Biosciences
Pulse Biosciences, Inc, is a bioelectric medicine company pursuing commercial introduction of our proprietary CellFX™ System harnessing the distinctive advantages of our patented Nano-Pulse Stimulation™ (NPS™) technology. NPS technology delivers nano-second pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of ongoing clinical trials, and with a growing patent portfolio, Pulse Biosciences is building a rich pipeline of transformative commercial applications.
Pulse Biosciences is preparing to launch the CellFX System in 2019 as a multi-application platform designed to address a broad range of dermatologic conditions. The initial commercial use will be in the clearance of common skin lesions, including sebaceous hyperplasia (SH) and seborrheic keratosis (SK) - two prevalent and difficult-to-treat benign skin conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction.
Stock Symbol: PLSE
65 articles with Pulse Biosciences
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - Sept. 18, 2019
9/18/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 61,250 shares of Pulse Biosciences common stock to four recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 16, 2019.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - Sept. 4, 2019
9/5/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 105,000 shares of Pulse Biosciences common stock to two recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 29, 2019.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - Aug. 16, 2019
8/16/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 48,000 shares of Pulse Biosciences common stock to six recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 15, 2019.
-
Pulse Biosciences Quarterly Investor Conference Call - Aug. 8, 2019
8/8/2019
Pulse Biosciences, Inc. reported recent corporate developments and financial results for the three- and six-month periods ended June 30, 2019.
-
Pulse Biosciences Announces Podium Presentation of Nano-Pulse Stimulation™ Technology at Major Aesthetic Procedures Conference
8/6/2019
Pulse Biosciences, Inc. announced its patented Nano-Pulse Stimulation™ technology will be featured in a series of podium presentations in the “Hot Topics” session of Controversies and Conversations in Lasers & Cosmetic Surgery.
-
Pulse Biosciences to Report Second Quarter 2019 Operational Highlights and Financial Results
7/25/2019
Pulse Biosciences, Inc., a novel bioelectric medicine company bringing to market its proprietary CellFX™ System announced that the Company will report second quarter 2019 operational highlights and financial results on Thursday, August 8, 2019.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - June 17, 2019
6/18/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,750 shares of Pulse Biosciences common stock to three recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on June 17, 2019.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - May 15, 2019
5/15/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 110,500 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on May 15, 2019.
-
Pulse Biosciences Quarterly Investor Conference Call - April 30, 2019
4/30/2019
Pulse Biosciences, Inc. reported recent corporate developments and financial results for the quarter ended March 31, 2019.
-
Pulse Biosciences to Report First Quarter 2019 Operational Highlights and Financial Results
4/18/2019
Pulse Biosciences, Inc., a novel medical therapy company bringing to market its proprietary CellFX™ System announced that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April 30, 2019.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - April 15, 2019
4/15/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 28,000 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on April 15, 2019.
-
Pulse Biosciences Announces Presentations at the 2019 American Society for Laser Medicine and Surgery Annual Conference
3/26/2019
Pulse Biosciences, Inc. announced that key findings from its clinical programs using Nano-Pulse Stimulation™ technology will be presented at the American Society for Laser Medicine and Surgery’s Annual Conference being held March 27-31, 2019, in Denver, CO.
-
Pulse Biosciences Appoints Mitchell Levinson to Board of Directors
3/19/2019
In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees - March 18, 2019
3/15/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 61,000 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on March 15, 2019.
-
Pulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting
3/1/2019
Pulse Biosciences, Inc. announced that clinical results from its recently completed Sebaceous Hyperplasia study will be presented at the American Academy of Dermatology Annual Meeting
-
Pulse Biosciences Submits 510(K) to U.S. FDA for CellFX™ System
2/28/2019
Pulse Biosciences, Inc., a novel medical therapy company bringing to market its proprietary CellFX™ System announced the Premarket Notification 510 submission to the U.S. Food and Drug Administration for its CellFX System.
-
Pulse Biosciences Grants Equity Incentive Awards to New Employees on February 15, 2019
2/15/2019
Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 37,250 shares of Pulse Biosciences common stock to eight new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on February 15, 2019.
-
Pulse Biosciences Quarterly Investor Conference Call - February 7, 2019
2/7/2019
First patient treated in the CellFX™ back acne clinical feasibility study
-
Pulse Biosciences to Report Fourth Quarter and Full Year 2018 Operational Highlights and Financial Results
1/29/2019
Pulse Biosciences, Inc. today announced that the Company will report fourth-quarter and full-year 2018 operational highlights and financial results on Thursday, February 7, 2019.
-
Pulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson
1/17/2019
− Ebbers named Executive Vice President and General Manager, Dermatology − Tyson named Vice President, Sales North America